Compare CRCT & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRCT | COLL |
|---|---|---|
| Founded | 1969 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.5B |
| IPO Year | 2021 | 2015 |
| Metric | CRCT | COLL |
|---|---|---|
| Price | $5.19 | $48.67 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $4.18 | ★ $47.50 |
| AVG Volume (30 Days) | 492.2K | ★ 515.8K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 18.27% | N/A |
| EPS Growth | ★ 27.98 | N/A |
| EPS | 0.37 | ★ 1.63 |
| Revenue | $714,492,000.00 | ★ $757,067,000.00 |
| Revenue This Year | $1.06 | $26.35 |
| Revenue Next Year | N/A | $3.67 |
| P/E Ratio | ★ $14.07 | $29.92 |
| Revenue Growth | N/A | ★ 26.34 |
| 52 Week Low | $3.94 | $23.23 |
| 52 Week High | $7.33 | $49.16 |
| Indicator | CRCT | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 59.44 | 70.71 |
| Support Level | $4.65 | $46.15 |
| Resistance Level | $5.27 | $49.16 |
| Average True Range (ATR) | 0.14 | 1.32 |
| MACD | 0.07 | -0.16 |
| Stochastic Oscillator | 87.90 | 92.11 |
Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.